Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.  

Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Elicio’s Broad Cancer-Vaccine Ambitions

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/7a58ee84-0073-43a6-8396-b05f013ec075/transcript

“Revenue cycle is really about solving two problems: generating an accurate receipt and then jumping through the fifty hoops to get paid.” says Dr. Michael Gao, CEO of Smarter Technologies. In this episode of Vanguards of Health Care, Gao joins Bloomberg Intelligence analyst Jonathan Palmer to explain how AI is transforming hospital revenue cycle management (RCM). He walks through Smarter’s approach to clinical intelligence and automation, why AI works best as a first pass with human supervision, and how smarter workflows can lift margins for hospitals operating on razor-thin economics. The conversation also explores Smarter’s formation with New Mountain Capital and Gao’s mission to reduce the trillion-dollar burden of health care administration.

&ldquo;Revenue cycle is really about solving two problems: generating an accurate receipt and then jumping through the fifty hoops to get paid.&rdquo; says Dr. Michael Gao, CEO of Smarter Technologies. In this episode of Vanguards of Health Care, Gao joins Bloomberg Intelligence analyst Jonathan Palmer to explain how AI is transforming hospital revenue cycle management (RCM). He walks through Smarter&rsquo;s approach to clinical intelligence and automation, why AI works best as a first pass with human supervision, and how smarter workflows can lift margins for hospitals operating on razor-thin economics. The conversation also explores Smarter&rsquo;s formation with New Mountain Capital and Gao&rsquo;s mission to reduce the trillion-dollar burden of health care administration.

Smarter Technologies’ Blueprint for AI-Driven Revenue Cycle Management

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f01be765-43f5-4f3f-994b-b3d201646db9/transcript

“Our mission is to create both strategic and financial returns by backing scalable technologies that can transform how biopharma operates.” Bill Taranto, president and general partner of the Merck Global Health Innovation Fund, joins Bloomberg Intelligence analyst Jonathan Palmer to break down how Merck’s $600 million evergreen venture arm invests at the intersection of biotech and health tech. Taranto explains why GHI focuses on pharma services across drug development, supply chain, patient access and real-world evidence, how ecosystem investing and private equity drive scale, and why AI and data are reshaping the future of pharma operations.

&ldquo;Our mission is to create both strategic and financial returns by backing scalable technologies that can transform how biopharma operates.&rdquo; Bill Taranto, president and general partner of the Merck Global Health Innovation Fund, joins Bloomberg Intelligence analyst Jonathan Palmer to break down how Merck&rsquo;s $600 million evergreen venture arm invests at the intersection of biotech and health tech. Taranto explains why GHI focuses on pharma services across drug development, supply chain, patient access and real-world evidence, how ecosystem investing and private equity drive scale, and why AI and data are reshaping the future of pharma operations.

Merck’s GHI Fund and the Push to Rewire Pharma's Future

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e33d651e-63ab-4303-b264-b3cc01027ca5/transcript

“We were a very valuable deep-science company that had the wrong business strategy,” Zymeworks CEO Ken Galbraith tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. In discussing the company’s strategic reset, Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances innovation with capital discipline. The conversation covers zanidatamab’s path to market, lessons from partnering with Jazz and BeOne, the value of asymmetric antibody design and why retaining upside through milestones and royalties could reshape long-term value creation.

&ldquo;We were a very valuable deep-science company that had the wrong business strategy,&rdquo; Zymeworks CEO Ken Galbraith tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. In discussing the company&rsquo;s strategic reset, Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances innovation with capital discipline. The conversation covers zanidatamab&rsquo;s path to market, lessons from partnering with Jazz and BeOne, the value of asymmetric antibody design and why retaining upside through milestones and royalties could reshape long-term value creation.

Zymeworks on Rethinking Risk, Royalties and R&D

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d885d277-28bd-4245-bb4a-b3ca014f0dfc/transcript

Elicio’s Broad Cancer-Vaccine Ambitions

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips